中国IgA肾病患者的长期结局
本研究基于北京大学第一医院2141例经活检证实的IgA肾病患者前瞻性队列,中位随访5.8年,发现24%进展至终末期肾病,15年肾脏生存率40%。时间平均蛋白尿与肾衰竭强相关,超过0.5 g/d时风险快速增加,提示现行治疗下长期预后仍不佳。
要点
- 中国IgA肾病患者长期预后不佳,15年肾脏生存率仅40%。
- 时间平均蛋白尿≥0.5 g/d与ESKD风险快速增加相关。
- 蛋白尿<0.3 g/d与0.3-0.5 g/d组长期肾脏生存无显著差异。
核心结论
- 当前治疗策略下IgA肾病患者长期结局仍较差,多数在15年内进展至ESKD。
- 时间平均蛋白尿≥0.5 g/d者肾脏结局更差,挑战了既往认为蛋白尿<1.0 g/d肾衰竭风险低的观点。
研究设计与样本
- 研究为来自中国北京大学第一医院的前瞻性IgA肾病队列。
- 纳入2141例经活检证实且随访至少12个月的IgA肾病患者。
- 采用Kaplan-Meier分析、Cox回归和线性混合模型估算的eGFR斜率评估肾脏结局。
主要发现
- 基线中位蛋白尿为1.26 g/d(Q1-Q3:0.65-2.40),eGFR为80 mL/min/1.73 m2(Q1-Q3:52-103)。
- 平均随访5.8±4.4年,509例(24%)进展至ESKD。
- 中位肾脏生存时间为12.4年,ESKD年发生率为41.1/1000人年,15年肾脏生存率为40%。
- 时间平均蛋白尿水平与肾衰竭强相关,校正后风险比1.76(95%CI 1.65-1.88)。
- 限制性立方样条分析显示时间平均蛋白尿超过0.5 g/d时ESKD风险快速增加。
关键数值与推荐
- 时间平均蛋白尿≥0.5 g/d与ESKD风险增加相关。
- 蛋白尿<0.3 g/d和0.3-0.5 g/d组长期肾脏生存无显著差异。
临床怎么用
- 临床应重视IgA肾病患者长期蛋白尿管理,将时间平均蛋白尿控制在0.5 g/d以下可能改善肾脏预后。
- 对于蛋白尿已控制在0.5 g/d以下的患者,进一步降低至<0.3 g/d的额外获益尚不明确。
局限性
- 研究为单中心前瞻性队列,结果外推需谨慎。
- 原文未报告其他局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The long-term prognosis of immunoglobulin A nephropathy (IgAN) and the optimal target for proteinuria treatment remain controversial. This study, utilizing a large prospective cohort from China, aims to assess the long-term outcomes of IgAN and to explore the definition of proteinuria remission. METHODS: We enrolled 2141 patients with biopsy-proven IgAN, all with at least 12 months of follow-up, from a prospective IgAN cohort at Peking University First Hospital. We utilized Kaplan-Meier analysis, Cox regression and an estimated glomerular filtration rate (eGFR) slope calculated via a linear mixed model to investigate kidney outcomes. RESULTS: The median (Q1, Q3) baseline proteinuria was 1.26 (0.65, 2.40) g/day, and the eGFR was 80 (52, 103) mL/min/1.73 m2. After a mean follow-up of 5.8 (±4.4) years, 509 (24%) patients progressed to end-stage kidney disease (ESKD). The median kidney survival time was 12.4 years, the annual event rate of ESKD was 41.1 per 1000 person-years and the 15-year kidney survival rate was 40%. Time-averaged proteinuria level was strongly associated with kidney failure (adjusted hazard ratio 1.76, 95% confidence interval 1.65 to 1.88). Restriction cubic spline analysis indicated that the risk of ESKD increases rapidly when time-average proteinuria exceeded 0.5 g/day. There was no significant difference in long-term kidney survival between patients with proteinuria <0.3 g/day and those with 0.3-0.5 g/day, with both groups demonstrating a better prognosis. CONCLUSION: The long-term outcomes for patients with IgAN under current treatment strategies remain poor, with most progressing to ESKD within 15 years. Patients with time-averaged proteinuria ≥0.5 g/day experience worse kidney outcomes, challenging the previous view that proteinuria <1.0 g/day was associated with a low risk of kidney failure.
引用
- Shen X, Chen P, Liu M, et al. Long-term outcomes of IgA nephropathy in China. Nephrol Dial Transplant. 2025. PMID: 39557651. doi:10.1093/ndt/gfae252
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。